Table 1.

Characteristics of patients who had MSK-IMPACT testing prior to EGFR TKI therapy (n = 200) or after EGFR TKI therapy (n = 136) or both (n = 38)

Clinical characteristicsPre EGFR-TKI, N (%)Post EGFR-TKI, N (%)Paired samples, N (%)
Total20013638
Age
 Median (range)63 (23–89)61 (29–86)62 (34–84)
Sex
 Male66 (33)95 (70)11 (29)
 Female134 (67)41 (30)27 (71)
Smoking
 Never-smoker118 (59)79 (58)22 (58)
 Former smoker82 (41)57 (42)16 (42)
 Median pack-year (range)6 (1–125)0 (0–110)0 (0–30)
HistologyBefore TKIAfter TKI
 Adenocarcinoma200 (100)133 (97.8)38 (100)*37 (97)
 Small-cell carcinoma0 (0)2 (1.5)0 (0)1 (3)
 Large cell neuroendocrine0 (0)1 (0.7)0 (0)0 (0)
EGFR mutation
 EGFR T790M0 (0)70 (52)0 (0)16 (42)
 Exon 19 deletion90 (45)78 (57)17 (45)
 L858R72 (36)43 (32)15 (39)
 Exon 20 insertions7 (3.5)1 (0.7)0 (0)
 Exon 18 deletion5 (2.5)4 (3)3 (8)
 Exon 19 insertion3 (1.5)1 (0.7)1 (3)
 L861Q6 (3)2 (1.5)0 (0)
 G719A3 (1.5)2 (1.5)0 (0)
 L747P3 (1.5)0 (0)0 (0)
 E709X+G719X4 (2)0 (0)0 (0)
 G719X+S768I2 (1)3 (2)0 (0)
 G719X+L861Q3 (1.5)0 (0)0 (0)
 EGFR-KDD2 (1)2 (1.5)2 (5)
Prior treatment
 Erlotinib0 (0)128 (94)0 (0)36 (95)
 Afatinib0 (0)6 (4)0 (0)2 (5)
 Dacomitinib0 (0)2 (1)0 (0)0 (0)